Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA4 | P22748 | 2/20 | 0.45 |
| ▸ | CA6 | P23280 | 2/20 | 0.45 |
| ▸ | CA7 | P43166 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TPMT | P51580 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29472005 | 1.00 | ALDH1A1 (0.59) | ALDH1A1HPGDTSHRTP53CA12 | |
| SCHEMBL30786930 | 0.88 | ALDH1A1 (0.54) | ALDH1A1HPGDTSHRTP53CA12 | |
| SCHEMBL22530492 | 0.88 | ALDH1A1 (0.54) | ALDH1A1HPGDTSHRTP53CA12 | |
| SCHEMBL13812238 | 0.87 | ALDH1A1 (0.60) | ALDH1A1HPGDTSHRCA12CA1 | |
| SCHEMBL1419879 | 0.85 | ALDH1A1 (0.62) | ALDH1A1HPGDTSHRCA12CA1 | |
| SCHEMBL28343052 | 0.85 | ALDH1A1 (0.50) | ALDH1A1HPGDTSHRTP53CA12 | |
| SCHEMBL15393730 | 0.84 | ALDH1A1 (0.45) | ALDH1A1HPGDTSHRCA1CA2 | |
| SCHEMBL2051393 | 0.84 | XDH (0.50) | KDM4EXDH | |
| SCHEMBL2820180 | 0.83 | ALDH1A1 (0.49) | ALDH1A1HPGDTSHRTP53CA12 | |
| SCHEMBL1267736 | 0.83 | KDM4E (0.57) | ALDH1A1HPGDTSHRTP53CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115160285-B | Thioamides ALDH 2 Agonist, preparation method and application | 云南大学 | 2022-11-29 | — | — | CN | disclosed |
| CN-115160285-A | Thioamides ALDH 2 Agonist, preparation method and application | 云南大学 | 2022-10-11 | — | — | CN | disclosed |
| US-20220185785-A1 | INHIBITORS OF CD40-CD154 BINDING | TONIX Pharmaceuticals Holding Corp (US) | 2022-06-16 | — | — | US | disclosed |
| US-20220185785-A1 | INHIBITORS OF CD40-CD154 BINDING | TONIX Pharmaceuticals Holding Corp (US) | 2022-06-16 | — | — | US | disclosed |
| EP-3952853-A1 | INHIBITORS OF CD40-CD154 BINDING | Tonix Pharmaceuticals Holding Corp. (US) | 2022-02-16 | — | — | EP | disclosed |
| CN-107024834-B | Compound and coloring composition | 住友化学株式会社 | 2021-11-23 | — | — | CN | disclosed |
| CN-107586469-B | Pigment composition, coloring composition, and coloring curable composition | 住友化学株式会社 | 2021-04-06 | — | — | CN | disclosed |
| CN-108355651-B | Ruthenium nano metal electrocatalyst and preparation method thereof | 电子科技大学 | 2021-02-05 | — | — | CN | disclosed |
| WO-2020210831-A1 | INHIBITORS OF CD40-CD154 BINDING | TONIX Pharmaceuticals Holding Corp (US) | 2020-10-15 | — | — | WO | disclosed |
| WO-2020210831-A1 | INHIBITORS OF CD40-CD154 BINDING | TONIX Pharmaceuticals Holding Corp (US) | 2020-10-15 | — | — | WO | disclosed |
| EP-2385039-A1 | 2-Iminoisoindolinone derivatives as thrombin receptor antagonists | Eisai R&D Management Co., Ltd. (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-7371866-B2 | Preparation of aromatic and heteroaromatic carboxylic acids by catalytic ozonolysis | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2008-05-13 | — | — | US | disclosed |
| US-7244730-B2 | 2-iminopyrrolidine derivatives | EISAI CO., LTD (JP) | 2007-07-17 | — | — | US | disclosed |
| US-7244730-B2 | 2-iminopyrrolidine derivatives | EISAI CO., LTD (JP) | 2007-07-17 | — | — | US | disclosed |
| WO-2005063385-A1 | METHOD FOR OXIDIZING SATURATED HYDROCARBONS | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2005-07-14 | — | — | WO | disclosed |
| US-20030216577-A1 | Preparation of aromatic and heteroaromatic carboxylic acids by catalytic ozonolysis | DSM FINE CHEMICALS AUSTRIA NFG GMBH & COKG (AT) | 2003-11-20 | — | — | US | disclosed |
| EP-1362840-A1 | Process for the preparation of aromatic and heteroaromatic carboxylic acids via catalytic ozonolysis | DSM Fine Chemicals Austria Nfg GmbH & Co KG (AT) | 2003-11-19 | — | — | EP | disclosed |
| US-6613930-B2 | Contacting 2-amino-4-nitrotoluene with HR/NaNO3 followed by heating; hydrogenation to reduce nitro group to amino group; reacting with NaNO2/HCl; adding cyanate source; oxidation to obtain 4-cyanobenzoic acid derivative | MILLENNIUM PHARMACEUTICALS, INC. | 2003-09-02 | — | — | US | disclosed |
| US-5466858-A | Ruthenium catalyst, high selectivity with a carboxylic acid | UBE INDUSTRIES, LTD. (JP) | 1995-11-14 | — | — | US | disclosed |
| US-4002635-A | FOR COLORING PLASTICS AND LACQUERS | CIBA-GEIGY CORPORATION (US) | 1977-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185785-A1 | INHIBITORS OF CD40-CD154 BINDING | CD40LG, CD40, CD4 | ALDH1A1 1606/4885HPGD 2304/4885TSHR 908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.